Replies to post #279642 on Amarin Corp Plc (AMRN)

[fsulevine]

Well, actually coming off a short week, I am personally disappointed with Vascepa's numbers this week. But now that they are going to be advertising again, I hope things pick up more each week.

[couldbebetter]

Indeed. This is now a pattern. While the board here is worried about
the prospect of a generic Vascepa, generic Lovaza is eating AMRN's lunch.

Perhaps a BP will acquire AMRN and then corner the raw material used and
launch an authorized generic at a price low enough to undercut generic
Lovaza and (if it is out there, generic Vascepa.) Maybe a generic
Vascepa will be the only way to win here, if AMRN is owned by a BP who
can dominate the raw material used to manufacture Vascepa. Imagine a
BP who can do that in a way that would price the authorized generic
for the US to destroy the competition in the US, and at the same time
determine the optimal price point for Europe to insure that Vascepa
sold there is a low cost high volume medication there. If AMRN's
China partner can follow suit in the potentially massive China market
to keep the price low enough to be widely used there as well, it could
mean world domintion for the Omega-3 market by one BP that has the
vision and gravitas to make it all happen.

JT right now cannot even deal with the neverending issue of generic
Lovaza. The question is why? JT is not competent nor is he qualified
to run AMRN. This has been obvious for a very long time. JT is poison.